ALBI Score Calculator: Objective Functional Reserve in Liver Cancer & Cirrhosis

Calculate the Albumin-Bilirubin (ALBI) score and grade (1, 2, 3) to objectively evaluate liver functional reserve without subjective clinical bias.

The Albumin-Bilirubin (ALBI) score is an evidence-based clinical model created by Dr. Philip J. Johnson and an international consortium in 2015 to evaluate liver functional reserve in patients with hepatocellular carcinoma (HCC) and chronic liver disease. Developed specifically to overcome the subjective limitations of the child pugh score calculator—namely, the observer variability in grading ascites and hepatic encephalopathy—ALBI relies exclusively on two objective, routinely measured serum biomarkers: albumin and bilirubin. By generating a continuous statistical function, the ALBI calculator stratifies patients into ALBI Grade 1, Grade 2, and Grade 3, offering fine-grained prognostic discrimination, particularly within Child-Pugh Class A.

Why ALBI Was Developed: The Child-Pugh Class A Dilemma

In the management of hepatocellular carcinoma, clinical trial protocols and clinical practice guidelines (such as the Barcelona Clinic Liver Cancer [BCLC] staging system) historically required patients to be in Child-Pugh Class A to qualify for curative surgical resection, locoregional therapies (such as radiofrequency ablation or transarterial chemoembolization, TACE), or systemic targeted therapies.

However, practicing oncologists and hepatologists recognized that Child-Pugh Class A is biologically heterogeneous. Some Class A patients maintain robust hepatocellular reserve and tolerate extensive hepatic resections without complications, whereas other Class A patients rapidly decompensate into liver failure following minor interventions. Because Child-Pugh assigns categorical points (1, 2, or 3) and relies on subjective assessments of ascites and encephalopathy, it lacks the resolution to differentiate between patients at the healthy end of Class A (score 5) and those with subclinical functional compromise (score 6). ALBI was engineered to solve this precise problem.

Mathematical Formula and International Standardization

The ALBI score utilizes a continuous mathematical formula derived from extensive Cox proportional hazards regression modeling across thousands of international liver cancer patients:

ALBI Score = (log10(Bilirubin in µmol/L) × 0.66) + (Albumin in g/L × -0.085)

Note the international laboratory units: total bilirubin must be converted to micromoles per liter (µmol/L), and serum albumin must be converted to grams per liter (g/L). Our automated ALBI calculator performs these unit normalizations seamlessly, allowing clinicians to input values in conventional US units (mg/dL and g/dL) or international SI units.

Based on the calculated numerical result, patients are categorized into three validated ALBI grades:

• ALBI Grade 1: Score ≤ -2.60. Represents the highest hepatic functional reserve. Median survival in HCC validation cohorts ranges from 18.5 to 85.6 months.

• ALBI Grade 2: Score > -2.60 and ≤ -1.39. Represents intermediate hepatic functional reserve. Median survival ranges from 9.4 to 46.5 months.

• ALBI Grade 3: Score > -1.39. Represents severely compromised liver reserve. Median survival is limited, ranging from 2.7 to 15.6 months.

Clinical Applications in Liver Resection, TACE, and Immunotherapy

The ALBI grade has demonstrated broad prognostic utility across multiple hepatology domains:

1. Surgical Resection for HCC: Patients with ALBI Grade 1 have significantly lower rates of post-hepatectomy liver failure (PHLF) and superior 5-year overall survival compared to patients with ALBI Grade 2, even when both groups are classified as Child-Pugh Class A.

2. Locoregional Therapy (TACE): Evaluating baseline ALBI grade helps prevent post-embolization liver failure. Patients with ALBI Grade 2 or 3 are at heightened risk of ischemic liver decompensation following TACE.

3. Systemic Targeted Therapy & Immunotherapy: Clinical trials evaluating atezolizumab plus bevacizumab, durvalumab plus tremelimumab, or tyrosine kinase inhibitors (sorafenib, lenvatinib) demonstrate that patients with ALBI Grade 1 achieve significantly longer progression-free and overall survival compared to higher grades.

Comparing ALBI with Child-Pugh and MELD

While ALBI eliminates subjective variables, it does not assess portal hypertension, coagulopathy (INR), or renal function. Therefore, ALBI is not a replacement for the child score calculator or MELD 3.0 in general cirrhosis care; rather, it is a specialized biomarker instrument tailored for oncologic stratification and hepatic reserve refinement.

Clinical takeaways

  • ALBI uses only albumin (g/L) and log10(bilirubin [µmol/L]), eliminating subjective exam bias.
  • Grade 1 (≤ -2.60), Grade 2 (-2.60 to -1.39), Grade 3 (> -1.39).
  • Sub-stratifies Child-Pugh Class A patients to optimize surgical and oncological decision-making.

Limitations

  • Does not evaluate portal hypertension (platelets, varices) or coagulopathy directly.
  • Not currently referenced in FDA drug package inserts for general non-oncologic drug dosing.
  • Altered by acute non-hepatic causes of hypoalbuminemia (e.g., nephrotic syndrome) or hyperbilirubinemia (hemolysis).

References

  1. Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550-558.
  2. Pinato DJ, et al. Clinical validation of the ALBI grade in hepatocellular carcinoma. J Hepatol. 2017;66(2):337-344.